I'm also glad you touched on the patent issue and intellectual property. You're right, there is public health care in both European states and Canada, and that's been an important part of not only our negotiating position, but also provincial participation in this. We've heard from the R and D branded side of the pharmaceutical industry, as well as the generics. We have an important generic industry here. When we have witnesses here who both generally agree it's a great agreement and are on opposite sides of that issue, we think we've struck the right balance.
How does the European Union view the balance between your patent link and the important impact that generics can play to keep costs low?